Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · IEX Real-Time Price · USD
1.760
+0.130 (7.98%)
At close: Jul 19, 2024, 4:00 PM
1.900
+0.140 (7.95%)
Pre-market: Jul 22, 2024, 7:24 AM EDT
Calidi Biotherapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for CLDI stock have an average target of 1.67, with a low estimate of 1.00 and a high estimate of 2.00. The average target predicts a decrease of -5.11% from the current stock price of 1.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CLDI stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $1 | Strong Buy | Initiates | $1 | -43.18% | Jun 27, 2024 |
| Baird | Baird | Buy Maintains $4.5 → $2 | Buy | Maintains | $4.5 → $2 | +13.64% | May 15, 2024 |
| Baird | Baird | Buy Maintains $9 → $4.5 | Buy | Maintains | $9 → $4.5 | +155.68% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $2 | Strong Buy | Maintains | $11 → $2 | +13.64% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +525.00% | Nov 22, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.63
from -17.30
EPS Next Year
-0.29
from -0.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 7.7M |
| Avg | n/a | n/a | n/a | n/a | 7.4M |
| Low | n/a | n/a | n/a | n/a | 7.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.65 | -0.29 | -0.30 |
| Avg | -0.63 | -0.29 | -0.30 |
| Low | -0.61 | -0.27 | -0.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.